Related Experiment Videos
[Therapy of atopic dermatitis in children. Study on the use of a desensitizing preparation]
Insights
Histaglobin (gamma globulin + histamine) injections effectively treated atopic dermatitis in children. The therapy significantly reduced symptoms like itching and redness with no adverse effects observed.
Area of Science:
- Immunology
- Dermatology
- Pediatrics
Context:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition affecting children.
- Current treatments for AD can have limitations and side effects.
- Histaglobin, a combination of gamma globulin and histamine, is explored as a therapeutic option.
Purpose:
- To evaluate the efficacy and safety of Histaglobin desensitization therapy in pediatric patients with atopic dermatitis.
- To assess the impact of Histaglobin on key clinical parameters of AD.
Summary:
- A study involving 42 children with atopic dermatitis assessed Histaglobin treatment via hypodermic injections.
- The therapy involved two phases: an initial nine-injection phase with increasing doses and a maintenance phase with less frequent injections.
- Key parameters monitored included prurigo, erythema, exudation, and scratching lesions, all of which showed significant improvement, with many symptoms resolving completely.
Impact:
- Histaglobin desensitization therapy demonstrated a high degree of efficacy in improving atopic dermatitis symptoms in children.
- The treatment was well-tolerated, with no adverse events reported during the study.
- These findings suggest Histaglobin is a potentially safe and effective treatment option for pediatric atopic dermatitis.
Abstract:
Children with Atopic Dermatitis have been treated with Histaglobin (gamma globulin + histamine) applied by hypodermic injections. The patients (42) were divided into three groups: the first one (ten cases) aged between 9 and 5 years; the second one (eight cases) between 5 and 2 years and the third one (twenty four cases) aged less than two years. The trial has been carried out in two phases: the first one consisted of nine injections with increasing doses ranging from 1/3 to 1 ampoule with 4-6 day intervals; the second one, "the maintenance period", was made by nine injections of 1 ampoule with increasing intervals from two up to four weeks. The following four parameters were checked along all the therapy period: prurigo, erythema, exudation, scratching lesions. All the listed symptoms have been observed to decrease of intensity mainly during the first phase, until the complete disappearance of some of them; the residual symptoms continued to have a further improvement during the second phase; in most case disappeared completely. Absolutely no troubles of any kind have been noticed. Consequently the Authors consider the desensitization therapy by Histaglobin on the whole satisfying.